Zealand Pharma AS (CHIX:ZEALC) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:ZEALC Zealand Pharma AS CHIX:ZEALC
55 GF Score
Price kr295.40
GF Value kr12,045.19
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Zealand Pharma AS FFO per Share?

FFO per Share only applies to REITs.

CHIX:ZEALC
55GF Score
Zealand Pharma AS CHIX:ZEALC
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Zealand Pharma AS (CHIX:ZEALC) Overvalued in 2026?

Based on GuruFocus' analysis, Zealand Pharma AS stock appears to be undervalued. The current stock price of kr295.40 is trading 97.5% below its estimated GF Value™ of kr12,045.19. GuruFocus considers Zealand Pharma AS to be Possible Value Trap.

Key valuation signals for CHIX:ZEALC:

  • FFO per Share:
  • GF Value™: kr12,045.19 vs. price of kr295.40 (97.5% below fair value)
  • GF Score™: 55/100 with 3 warning signs

No single metric tells the full story. See the CHIX:ZEALC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zealand Pharma AS Business Description

Address Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
55GF Score

Get the complete analysis for CHIX:ZEALC

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr295.40
Price
kr12,045.19
GF Value